IRCT20200418047121N2 IRCT 2020-05-05 Kermanshah University of Medical Sciences Stem cell therapy in COVID-19 Investigation the adipose and placenta-derived mesenchymal stem cells effect on the respiratory distress syndrome in patients with COVID-19: a pilot study 2020-05-09 anticipated 6 Complete https://irct.ir/trial/47275 interventional Randomization: Not randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Blinding description: No information will be given to clinical evaluators and participants as to which group received the cells and which group did not. 1-2 COVID-19. Intervention 1: Intervention group: Three Patients suffering from COVID-19 with acute respiratory infections and severe lung involvement will be allocated to this group under the supervision of the medical staff. Those patients with severe symptoms (pneumonia and ARDS) will be suggested to join this pilot study and after obtaining the written informed consent, they participate in this investigation at Emam Reza hospital (at transplantation ward). Afterward, 1 × 106 cells/Kg of weight are prepared for transplantation in addition to common treatment protocol. Cell transplantation is repeated once every 3-4 days during a 14-day period (totally three doses). After cell transplantation, patients are assessed for two weeks, all the symptoms and side effects such as allergic reactions and secondary infections also the level of the cytokines variation, the level of CRP and the oxygen saturation, lymphocyte count, the chest CT and the respiratory rate will be assessed and compared with control group. Intervention 2: Control group: just receive the common treatment. Patients are assessed for two weeks, all the clinical symptoms such as the level of the cytokines, the level of CRP and the oxygen saturation, lymphocyte count, the chest CT and the respiratory rate are examined. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information